NCT05166265View on ClinicalTrials.gov

Clinical Investigation Study of Safety and Performance of the Sentio System.

NAActive, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

February 19, 2024

Study Completion Date

November 30, 2025

Conditions
Hearing Loss, ConductiveHearing Loss, MixedHearing Loss, Unilateral
Interventions
DEVICE

Active transcutaneous bone conduction hearing system

The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.

Trial Locations (6)

30625

HNO-Klinik Medizinische Hochschule Hanover, Hanover

79106

Universitätsklinikum Freiburg Universitätsklinik für Hals,- Nasen und Ohrenheilkunde, Freiburg im Breisgau

9700 RB

ENT Department, University Medical Center Groningen, Groningen

6500 HB

ENT department Radboud University Medical Center (Radboud UMC), Nijmegen

B15 2GW

ENT - University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge

Sponsors

Lead Sponsor

Oticon Medical
All Listed Sponsors
lead

Oticon Medical

INDUSTRY

NCT05166265 - Clinical Investigation Study of Safety and Performance of the Sentio System. | Biotech Hunter | Biotech Hunter